clinical trial · NCT06373146
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly and Company·phase2·active not recruiting·n = 392
ObesityTirzepatideMibavademabTirzepatide-PlaceboMibavademab-Placebo
brief summary
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
started
Apr 24, 2024
primary completion
Dec 15, 2025
completion
Apr 1, 2026
last updated
Jan 22, 2026
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol